LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Recruiting · NCT04733430 · Observational (researchers observe without assigning treatment) · Lead sponsor: Karl Landsteiner Institute for Lung Research and Pneumological Oncology
View the official record on ClinicalTrials.gov →What this trial is about
This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.
Who can take part
Inclusion criteria
- Informed consent
- Histologically confirmed lung cancer
- Age ≥ 18 years
- Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
Where it is running
1 location listed.
- Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie - Vienna, Austria